DOP2010000253A - Sistema de administracion de drogas con efecto estabilizante - Google Patents
Sistema de administracion de drogas con efecto estabilizanteInfo
- Publication number
- DOP2010000253A DOP2010000253A DO2010000253A DO2010000253A DOP2010000253A DO P2010000253 A DOP2010000253 A DO P2010000253A DO 2010000253 A DO2010000253 A DO 2010000253A DO 2010000253 A DO2010000253 A DO 2010000253A DO P2010000253 A DOP2010000253 A DO P2010000253A
- Authority
- DO
- Dominican Republic
- Prior art keywords
- matrix
- drug administration
- stabilizing effect
- administration system
- graft copolymer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7007—Drug-containing films, membranes or sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
Abstract
Un sistema de administración de drogas también usado como forma de dosificación unitaria que comprende una matriz de película delgada soluble en agua, en donde la matriz comprende: a) un copolímero de injerto polivinilalcoholpolietilenglicol (copolímero de injerto PVA-PEG) como polímero de matriz soluble en agua; b) un ingrediente activo que es un esteroide en el cual las posiciones 6 y 7 de la estructura esteroide son ambas un residuo eCH2-; y la mencionada matriz de polímero tiene un espesor de menos de 300 pm.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08002633 | 2008-02-13 | ||
EP08162105 | 2008-08-08 | ||
EP08105842 | 2008-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
DOP2010000253A true DOP2010000253A (es) | 2010-08-31 |
Family
ID=40957307
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DO2010000253A DOP2010000253A (es) | 2008-02-13 | 2010-08-13 | Sistema de administracion de drogas con efecto estabilizante |
Country Status (26)
Country | Link |
---|---|
US (1) | US20110052699A1 (es) |
EP (1) | EP2252261A2 (es) |
JP (1) | JP2011511816A (es) |
KR (1) | KR20100117603A (es) |
CN (1) | CN102006857B (es) |
AR (1) | AR070379A1 (es) |
AU (1) | AU2009214307A1 (es) |
BR (1) | BRPI0908231A2 (es) |
CA (1) | CA2714598A1 (es) |
CL (1) | CL2009000328A1 (es) |
CO (1) | CO6321222A2 (es) |
CR (1) | CR11630A (es) |
DO (1) | DOP2010000253A (es) |
EA (1) | EA018330B1 (es) |
EC (1) | ECSP10010399A (es) |
HN (1) | HN2010001610A (es) |
IL (1) | IL206927A0 (es) |
MA (1) | MA32055B1 (es) |
MX (1) | MX2010008945A (es) |
NZ (1) | NZ587309A (es) |
PA (1) | PA8815901A1 (es) |
PE (1) | PE20091574A1 (es) |
TW (1) | TW200940069A (es) |
UY (1) | UY31659A1 (es) |
WO (1) | WO2009100871A2 (es) |
ZA (1) | ZA201006518B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010057594A1 (en) * | 2008-11-21 | 2010-05-27 | Bayer Schering Pharma Aktiengesellschaft | Drug delivery system |
CN102018657B (zh) * | 2009-09-11 | 2014-01-22 | 上海市计划生育科学研究所 | 含孕激素的固体分散体及其制备方法,以及包含所述固体分散体的组合物 |
HUP0900698A2 (en) * | 2009-11-06 | 2011-06-28 | Richter Gedeon Nyrt | Pharmaceutical compositions of enhanced stability containing drospirenone and ethynyl estradiol and process for their preparation |
AR081670A1 (es) | 2010-06-29 | 2012-10-10 | Leon Farma Sa Lab | Composicion farmaceutica que comprende drospirenona y kit anticonceptivo |
US11351122B1 (en) | 2010-07-28 | 2022-06-07 | Laboratorios Leon Farma Sa | Synthetic progestogens and pharmaceutical compositions comprising the same |
US10849857B2 (en) | 2010-07-28 | 2020-12-01 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
US9603860B2 (en) | 2010-07-28 | 2017-03-28 | Laboratorios Leon Farma Sa | Pharmaceutical compositions comprising active drugs, contraceptive kits comprising active drugs, and methods of administering the same |
EP2874824A1 (en) | 2012-07-23 | 2015-05-27 | Crayola LLC | Dissolvable films and methods of using the same |
WO2016025911A1 (en) * | 2014-08-14 | 2016-02-18 | Brown University | Compositions for stabilizing and delivering proteins |
TWI525110B (zh) * | 2014-12-24 | 2016-03-11 | 財團法人工業技術研究院 | 聚合物、及包含其之醫藥組合物 |
JPWO2016163403A1 (ja) * | 2015-04-07 | 2018-02-01 | ニプロ株式会社 | 経口フィルム製剤 |
US20180355165A1 (en) * | 2015-12-02 | 2018-12-13 | Nippon Shokubai Co., Ltd. | Water-soluble film and manufacturing method therefor |
CA3105187A1 (en) | 2018-06-28 | 2020-01-02 | Arx, Llc | Dispensing method for producing dissolvable unit dose film constructs |
CN115624566B (zh) * | 2022-12-22 | 2023-03-10 | 广东省人民医院 | 一种腹膜透析液及其制备方法和应用 |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4136162A (en) * | 1974-07-05 | 1979-01-23 | Schering Aktiengesellschaft | Medicament carriers in the form of film having active substance incorporated therein |
JPS56140915A (en) * | 1980-04-07 | 1981-11-04 | Yamanouchi Pharmaceut Co Ltd | Pharmaceutical preparation for solid drug |
DE3347125A1 (de) * | 1983-12-22 | 1985-07-11 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mehrstufenkombinationspraeparat und seine verwendung zur oralen kontrazeption |
US4764378A (en) * | 1986-02-10 | 1988-08-16 | Zetachron, Inc. | Buccal drug dosage form |
US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
WO1993023011A1 (en) * | 1992-05-18 | 1993-11-25 | Minnesota Mining And Manufacturing Company | Transmucosal drug delivery device |
DE4426709A1 (de) * | 1994-07-20 | 1996-01-25 | Schering Ag | Steroidale Sexualhormone enthaltende feste Arzneiformen |
DE19646392A1 (de) * | 1996-11-11 | 1998-05-14 | Lohmann Therapie Syst Lts | Zubereitung zur Anwendung in der Mundhöhle mit einer an der Schleimhaut haftklebenden, Pharmazeutika oder Kosmetika zur dosierten Abgabe enthaltenden Schicht |
US6552024B1 (en) * | 1999-01-21 | 2003-04-22 | Lavipharm Laboratories Inc. | Compositions and methods for mucosal delivery |
CH693905A5 (de) * | 1999-04-15 | 2004-04-15 | Eprova Ag | Stabile kristalline Salze von 5-Methyltetrahydrofolsäure. |
US6264981B1 (en) * | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
US20050074487A1 (en) * | 1999-12-16 | 2005-04-07 | Tsung-Min Hsu | Transdermal and topical administration of drugs using basic permeation enhancers |
US20030092658A1 (en) * | 2001-02-02 | 2003-05-15 | Meyers Rachel E. | Novel human enzyme family members and uses thereof |
SK14632002A3 (sk) * | 2000-04-12 | 2003-03-04 | Schering Aktiengesellschaft | Substituované estratriény a ich použitie ako selektívne účinných estrogénov |
EP1216712A1 (en) * | 2000-12-20 | 2002-06-26 | Schering Aktiengesellschaft | Cyclodextrin-drospirenone inclusion complexes |
CA2419089A1 (en) * | 2001-07-27 | 2003-03-05 | Tatsuki Shinoda | Composition comprises sustained-release fine particles for quick-disintegrating tablets in the buccal cavity and manufacturing method thereof |
DE10226326A1 (de) * | 2002-06-11 | 2004-01-15 | Schering Ag | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene |
US20040208931A1 (en) * | 2002-12-30 | 2004-10-21 | Friend David R | Fast dissolving films for oral administration of drugs |
US20070059346A1 (en) * | 2003-07-01 | 2007-03-15 | Todd Maibach | Film comprising therapeutic agents |
PE20050496A1 (es) * | 2003-07-24 | 2005-06-12 | Smithkline Beecham Corp | Peliculas que se disuelven por via oral |
KR20060126688A (ko) * | 2003-12-09 | 2006-12-08 | 다이닛본 스미토모 세이야꾸 가부시끼가이샤 | 약물-함유 입자 및 그 입자를 함유하는 고형 제제 |
US20050220825A1 (en) * | 2004-03-10 | 2005-10-06 | Adrian Funke | Molecular dispersions of drospirenone |
DE102004023984A1 (de) * | 2004-05-14 | 2005-12-08 | Hf Arzneimittelforschung Gmbh | Filmförmiges, oral zu verabreichendes Arzneimittel, enthaltend Estriol |
US20060105038A1 (en) * | 2004-11-12 | 2006-05-18 | Eurand Pharmaceuticals Limited | Taste-masked pharmaceutical compositions prepared by coacervation |
DE102005015128B4 (de) * | 2005-03-31 | 2008-12-11 | Bayer Schering Pharma Aktiengesellschaft | Wafer enthaltend Steroidhormone |
DE102005058569B4 (de) * | 2005-12-08 | 2010-07-15 | Lts Lohmann Therapie-Systeme Ag | Schaumwafer mit Polyvinylalkohol-Polyethylenglycol-Pfropfcopolymer |
DE102005062270A1 (de) * | 2005-12-24 | 2007-06-28 | Bayer Technology Services Gmbh | Geschmacksmaskierung von Pulvern |
DE102006003512A1 (de) * | 2006-01-24 | 2007-08-02 | Bayer Schering Pharma Ag | Plättchenförmige Arzneimittel zur transbukkalen Applikation von Arzneistoffen |
GB0607105D0 (en) * | 2006-04-10 | 2006-05-17 | Leuven K U Res & Dev | Enhancing solubility and dissolution rate of poorly soluble drugs |
DE102006027792A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Antidepressiva-Kombinations-Wafer |
DE102006027796A1 (de) * | 2006-06-16 | 2007-12-20 | Lts Lohmann Therapie-Systeme Ag | Estrogen-Gestagen-Kombinationen |
-
2009
- 2009-02-10 CA CA2714598A patent/CA2714598A1/en not_active Abandoned
- 2009-02-10 US US12/867,165 patent/US20110052699A1/en not_active Abandoned
- 2009-02-10 BR BRPI0908231-0A patent/BRPI0908231A2/pt not_active IP Right Cessation
- 2009-02-10 NZ NZ587309A patent/NZ587309A/xx not_active IP Right Cessation
- 2009-02-10 AU AU2009214307A patent/AU2009214307A1/en not_active Abandoned
- 2009-02-10 CN CN2009801052087A patent/CN102006857B/zh not_active Expired - Fee Related
- 2009-02-10 MX MX2010008945A patent/MX2010008945A/es not_active Application Discontinuation
- 2009-02-10 EA EA201001244A patent/EA018330B1/ru not_active IP Right Cessation
- 2009-02-10 JP JP2010546253A patent/JP2011511816A/ja active Pending
- 2009-02-10 EP EP09710685A patent/EP2252261A2/en not_active Withdrawn
- 2009-02-10 WO PCT/EP2009/000904 patent/WO2009100871A2/en active Application Filing
- 2009-02-10 KR KR1020107017866A patent/KR20100117603A/ko not_active Application Discontinuation
- 2009-02-13 AR ARP090100519A patent/AR070379A1/es unknown
- 2009-02-13 PA PA20098815901A patent/PA8815901A1/es unknown
- 2009-02-13 CL CL2009000328A patent/CL2009000328A1/es unknown
- 2009-02-13 PE PE2009000220A patent/PE20091574A1/es not_active Application Discontinuation
- 2009-02-13 TW TW098104763A patent/TW200940069A/zh unknown
- 2009-02-13 UY UY031659A patent/UY31659A1/es not_active Application Discontinuation
-
2010
- 2010-07-11 IL IL206927A patent/IL206927A0/en unknown
- 2010-08-02 MA MA33052A patent/MA32055B1/fr unknown
- 2010-08-12 EC EC2010010399A patent/ECSP10010399A/es unknown
- 2010-08-13 DO DO2010000253A patent/DOP2010000253A/es unknown
- 2010-08-13 CO CO10100007A patent/CO6321222A2/es active IP Right Grant
- 2010-08-13 CR CR11630A patent/CR11630A/es not_active Application Discontinuation
- 2010-08-13 HN HN2010001610A patent/HN2010001610A/es unknown
- 2010-09-10 ZA ZA2010/06518A patent/ZA201006518B/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20110052699A1 (en) | 2011-03-03 |
EP2252261A2 (en) | 2010-11-24 |
PA8815901A1 (es) | 2009-09-17 |
AR070379A1 (es) | 2010-03-31 |
JP2011511816A (ja) | 2011-04-14 |
BRPI0908231A2 (pt) | 2015-07-21 |
CO6321222A2 (es) | 2011-09-20 |
CN102006857A (zh) | 2011-04-06 |
UY31659A1 (es) | 2009-09-30 |
AU2009214307A1 (en) | 2009-08-20 |
PE20091574A1 (es) | 2009-11-12 |
KR20100117603A (ko) | 2010-11-03 |
CL2009000328A1 (es) | 2010-07-19 |
HN2010001610A (es) | 2013-10-20 |
IL206927A0 (en) | 2010-12-30 |
CR11630A (es) | 2010-10-05 |
ZA201006518B (en) | 2013-02-27 |
WO2009100871A2 (en) | 2009-08-20 |
MA32055B1 (fr) | 2011-02-01 |
EA201001244A1 (ru) | 2011-04-29 |
NZ587309A (en) | 2012-09-28 |
ECSP10010399A (es) | 2010-09-30 |
TW200940069A (en) | 2009-10-01 |
WO2009100871A3 (en) | 2009-12-23 |
CN102006857B (zh) | 2013-06-26 |
EA018330B1 (ru) | 2013-07-30 |
CA2714598A1 (en) | 2009-08-20 |
MX2010008945A (es) | 2010-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2010000253A (es) | Sistema de administracion de drogas con efecto estabilizante | |
DOP2016000132A (es) | Sistema de administración farmacologico | |
ES2525530T3 (es) | Sistemas de administración oral de liberación controlada | |
RS52367B (en) | GLATIRAMER ACETATE FORMULATION FORMATED VOLUMES AND APPLICATION PROCEDURES | |
CR20110072A (es) | Sistema de administración de drogas que contiene progestina | |
AR073704A1 (es) | Sistema de administracion transdermal de droga para principios activos liquidos que tiene una capa de matriz adhesiva que incluye un ingrediente farmaceutico activo que es seleccionado entre selegilina y rivastigmina | |
AR072492A1 (es) | Dispositivo y administracion transdermica de estrogeno | |
UY31957A (es) | Metodo anticonceptivo mejorado | |
SV2008003106A (es) | Composicion farmaceutica estable que contiene docetaxel y un metodo para fabricarla | |
IL299897B1 (en) | Devices and methods for administering multiple units of drug | |
NZ608239A (en) | Aqueous drug delivery system comprising off - flavor masking agent | |
BR112012018449A2 (pt) | tira dental para administração de tratamento oral | |
AR061860A1 (es) | Prepracion farmaceutica para la administracion oral con liberacion controlada de ingrediente activo en el intestino delgado y metodo para su fabricacion | |
GB2583855A8 (en) | Transmucosal delivery device and method of manufacturing same | |
WO2015001087A3 (en) | Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition | |
AR089765A1 (es) | Un sistema para el suministro de un farmaco | |
PE20160534A1 (es) | Sistema de administracion intrauterina | |
AR070375A1 (es) | Sistemas de administracion de drogas que contienen estradiol | |
CU20100165A7 (es) | Sistema de administración de drogas con efecto estabilizante | |
AR096223A1 (es) | Pastilla de nicotina para administración oral | |
NI201600077A (es) | Sistema de administración farmacológico | |
TN2010000375A1 (en) | Drug delivery system with stabilising effect | |
TH128470A (th) | ระบบนำส่งยาด้วยผลการทำให้เกิดความเสถียร | |
UY28624A1 (es) | Compuesto y forma de dosificación que comprende una mólecula anfifilica como vehiculo de suspensión | |
AR110595A1 (es) | Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos |